The Conflicting Role of Myeloid Cells in CAR-T Cell Therapy - PubMed
7 hours ago
- #Myeloid cells
- #CAR-T therapy
- #Cancer immunotherapy
- CAR-T cell therapy is transforming cancer treatment for hematological malignancies but faces challenges in solid tumors due to the tumor microenvironment.
- Myeloid cells play a dual role in CAR-T therapy, influencing both efficacy and associated toxicities.
- Key CAR-T-associated toxicities involving myeloid cells include cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and hemophagocytic lymphohistiocytosis-like syndrome (HLH).
- Strategies to mitigate these toxicities focus on modulating myeloid cell activity.
- Myeloid cells can either suppress or enhance CAR-T cell function, presenting opportunities for therapeutic intervention.
- Combination therapies targeting myeloid cells alongside CAR-T cell therapy are being explored to improve outcomes.